Uppdrag | 7 April 2025

Setterwalls advises Guard Therapeutics AB in connection with a rights issue

Responsive image

Setterwalls advises Guard Therapeutics International AB (publ) (“Guard Therapeutics”) in connection with a rights issue of shares.

Guard Therapeutics is a Swedish biotechnology company developing innovative drugs in areas with significant medical needs, with a particular focus on kidney disease. The company’s primary drug candidate RMC-035 is in clinical phase and is being developed as a kidney-protective treatment in open-heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market.

Through the rights issue, Guard Therapeutics will receive issue proceeds of approximately SEK 120 million before issue costs.

  • This field is for validation purposes and should be left unchanged.

Do you want to get in touch with us?

Please fill out the form and we will contact you as soon as possible.